Jpmorgan Chase & CO Esperion Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,921,707 shares of ESPR stock, worth $5.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,921,707
Previous 2,454,216 21.7%
Holding current value
$5.23 Million
Previous $5.4 Million 48.75%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$1.44 - $2.34 $766,812 - $1.25 Million
-532,509 Reduced 21.7%
1,921,707 $2.77 Million
Q4 2024

Feb 12, 2025
BUY
$1.61 - $3.83 $620,009 - $1.47 Million
385,099 Added 18.61%
2,454,216 $5.4 Million
Q3 2024

Dec 26, 2024
BUY
$1.61 - $2.73 $31,536 - $53,475
19,588 Added 0.96%
2,069,117 $3.41 Million
Q3 2024

Nov 08, 2024
BUY
$1.61 - $2.73 $31,536 - $53,475
19,588 Added 0.96%
2,069,117 $3.41 Million
Q2 2024

Dec 26, 2024
SELL
$1.84 - $3.24 $36,041 - $63,465
-19,588 Reduced 0.95%
2,049,529 $4.55 Million
Q2 2024

Aug 12, 2024
SELL
$1.84 - $3.24 $65,452 - $115,253
-35,572 Reduced 1.71%
2,049,529 $4.55 Million
Q1 2024

Dec 26, 2024
BUY
$2.02 - $3.02 $32,287 - $48,271
15,984 Added 0.77%
2,085,101 $5.59 Million
Q1 2024

May 10, 2024
BUY
$2.02 - $3.02 $449,714 - $672,345
222,631 Added 11.95%
2,085,101 $5.59 Million
Q4 2023

Dec 26, 2024
SELL
$0.73 - $3.08 $150,852 - $636,472
-206,647 Reduced 9.99%
1,862,470 $5.57 Million
Q4 2023

Feb 12, 2024
SELL
$0.73 - $3.08 $1,359 - $5,734
-1,862 Reduced 0.1%
1,862,470 $5.57 Million
Q3 2023

Nov 14, 2023
BUY
$0.96 - $1.79 $1.57 Million - $2.94 Million
1,640,585 Added 733.23%
1,864,332 $1.83 Million
Q2 2023

Aug 11, 2023
BUY
$1.2 - $1.76 $44,342 - $65,035
36,952 Added 19.78%
223,747 $311,000
Q1 2023

May 18, 2023
BUY
$1.46 - $7.3 $82,485 - $412,428
56,497 Added 43.36%
186,795 $297,000
Q1 2023

May 11, 2023
SELL
$1.46 - $7.3 $358,500 - $1.79 Million
-245,548 Reduced 65.33%
130,298 $207,000
Q4 2022

Feb 13, 2023
SELL
$5.09 - $8.5 $127,199 - $212,415
-24,990 Reduced 6.23%
375,846 $2.34 Million
Q3 2022

Nov 14, 2022
SELL
$5.45 - $8.13 $2.61 Million - $3.9 Million
-479,687 Reduced 54.48%
400,836 $2.69 Million
Q2 2022

Aug 11, 2022
BUY
$4.77 - $6.67 $604,277 - $844,975
126,683 Added 16.81%
880,523 $5.6 Million
Q1 2022

May 11, 2022
BUY
$3.34 - $5.56 $2.13 Million - $3.54 Million
636,537 Added 542.64%
753,840 $3.5 Million
Q4 2021

Feb 10, 2022
BUY
$4.81 - $11.92 $148,378 - $367,708
30,848 Added 35.68%
117,303 $587,000
Q3 2021

Nov 12, 2021
BUY
$11.34 - $21.37 $980,399 - $1.85 Million
86,455 New
86,455 $1.04 Million

Others Institutions Holding ESPR

# of Institutions
184
Shares Held
106M
Call Options Held
139K
Put Options Held
604K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $181M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email